Ann: IHL-42X patent update & open label extension study approval, page-108

I found an (old) article on ANZCTR website (just google search IHL42X & the link will come up) that has the details on the initial Phase 2A trial - it's administered in blister-pack tablet form.

Reading through the "inclusion" & "exclusion" rules for the trial participants was interesting. To be included, you must "Have experimented with cannabinoids previously (self-disclosure). This includes any cannabis product (marijuana, skunk, ‘weed’)" but also further down, it then says you must "Have no history of past substance abuse or current abuse of illicit drugs".

Um....? Haha.

Anyway, hope that answers the question for method of delivery.